Prepulse Inhibition of Startle in Cocaine Dependence - 7

This study has been completed.

First Received: April 18, 2001 Last Updated: November 3, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York MDRU
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00015249

Purpose

The purpose of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Amantadine	Phase I

Study Type:	Interventional
Study Design:	Diagnostic, Double-Blind, Placebo Control
Official Title:	Prepulse Inhibition of Startle in Cocaine Dependence (Human)

Resource links provided by NLM:

Drug Information available for: Amantadine sulfate Amantadine hydrochloride Amantadine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Percent prepulse inhibition
Cocaine assessment

Estimated Enrollment:	0
Study Start Date:	February 1997

Detailed Description:

The objective of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Cocaine dependence. Male. Right handed. Negative urine for cocaine

Exclusion Criteria:

Positive urine for cocaine. History of head trauma. Significant medical disease.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00015249

Locations

United States, New York
New York MDRU
New York, New York, United States, 10010

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York MDRU

Investigators

Principal Investigator:

John Rotrosen, M.D.

New York MDRU

More Information

No publications provided

Study ID Numbers:	NIDA-5-0013-7, Y01-5-0013-7
Study First Received:	April 18, 2001
Last Updated:	November 3, 2005
ClinicalTrials.gov Identifier:	NCT00015249 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Anti-Infective Agents
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Disorders of Environmental Origin
Antiparkinson Agents
Antiviral Agents
Pharmacologic Actions

Pathologic Processes
Sensory System Agents
Analgesics, Non-Narcotic
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Dopamine Agents
Peripheral Nervous System Agents
Analgesics
Amantadine
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 22, 2009